

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 November 2020 (19.11.2020)



(10) International Publication Number
WO 2020/232154 A3

(51) International Patent Classification:
C12Q 1/6886 (2018.01) A61P 35/04 (2006.01)
C12Q 1/6883 (2018.01)

(21) International Application Number:
PCT/US2020/032722

(22) International Filing Date:
13 May 2020 (13.05.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/847,810 14 May 2019 (14.05.2019) US
62/855,910 31 May 2019 (31.05.2019) US

(71) Applicant: SIERRA ONCOLOGY, INC. [US/US];
Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(72) Inventors: HASSIG, Christian, Andrew; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). STROUSE, Bryan, William; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). HANSEN, Ryan, James; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). ANDERES, Kenna, Lynn; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). MILUTINOVIC, Snezana; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). YOU, Angie, J.; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). KLENCKE, Barbara; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). KOWALSKI, Mark; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(74) Agent: SCARR, Rebecca B. et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, MA 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
24 December 2020 (24.12.2020)



WO 2020/232154 A3

(54) Title: METHODS OF TREATING CANCER USING CHK1 INHIBITORS

(57) Abstract: This disclosure provides methods of using a checkpoint kinase 1 (Chk1) inhibitor in the treatment of cancer in a subject having at least an intermediate tumor mutational burden (TMB), or a genetic abnormality in one or more particular genes associated with replicative stress. Accordingly, methods of treating cancer in a subject having at least an intermediate tumor mutational burden (TMB-I) are provided. Also provided are methods of treating cancer in a subject having a genetic abnormality in one or more particular genes selected from cell cycle regulation genes, replication stress genes, oncogenic driver mutations and DNA damage response and repair network genes. Methods of selecting subjects for Chk1 inhibition therapy are provided. The methods can include administering to the subject an effective amount of a SRA737 compound, in some cases in combination with low dose gemcitabine.